Respiri Limited: Key Outcomes from the 2025 General Meeting

Key Highlights

• All Resolutions Passed: Resolutions on share issuance and ratifications were approved with strong support.
• Voting Transparency: Detailed results reflect shareholder alignment with strategic goals.
• Continued Focus on Innovation: Progress supports the development of Respiri’s asthma management solutions.

Respiri Limited (ASX: RSH), a pioneering e-health SaaS company, conducted its general meeting on January 6, 2025, with all proposed resolutions successfully passed. This outcome underscores shareholder confidence in Respiri’s (ASX: RSH) strategic direction and its mission to improve respiratory health worldwide.

This article explores the meeting’s resolutions, voting results, and what they signify for Respiri’s (ASX: RSH) growth trajectory and its flagship product, wheezo®.

Understanding the Resolutions: Strategic Approvals

The 2025 General Meeting centered around three key resolutions:

1. Approval to Issue Initial Consideration Shares to Orb Health, Inc.

This resolution authorized the issuance of initial shares to Orb Health, Inc., supporting a collaborative approach between the two companies. Orb Health’s integration aligns with Respiri’s (ASX: RSH) strategic goals to expand its capabilities in asthma and respiratory health management.

Voting Outcome:

• For: 99.53%
• Against: 0.47%
• Result: Carried

The overwhelming approval highlights investor enthusiasm for partnerships that enhance Respiri’s (ASX: RSH) value proposition.

2. Approval to Issue Additional Shares to Orb Health, Inc.

Beyond the initial consideration, shareholders approved the issuance of additional shares, further cementing the partnership with Orb Health.

Voting Outcome:

• For: 99.52%
• Against: 0.48%
• Result: Carried

This resolution strengthens the financial and operational foundation of the collaboration, paving the way for greater market impact.

3. Ratification and Approval of Prior Issue of Shares

The third resolution ratified and approved previous share issuances, ensuring compliance and reinforcing transparency.

Voting Outcome:

• For: 99.30%
• Against: 0.70%
• Result: Carried

This ratification demonstrates Respiri’s (ASX: RSH) commitment to governance standards and shareholder trust.

Voting Transparency: A Commitment to Stakeholders

Respiri’s (ASX: RSH) detailed disclosure of voting results reflects its commitment to transparency and accountability. Key aspects of the voting process include:

• Proxies Received: Shareholders provided clear instructions on their voting preferences, with proxies overwhelmingly favoring the resolutions.
• Abstentions: Minimal abstentions and exclusions indicate broad engagement from shareholders.
• Alignment with Strategy: The near-unanimous support underscores alignment between shareholders and management on the company’s vision.

Such transparency fosters confidence among existing and potential investors, reinforcing Respiri’s (ASX: RSH) reputation as a trusted entity in the health-tech sector.

wheezo®: A Revolution in Respiratory Health

At the core of Respiri’s (ASX: RSH) mission lies its groundbreaking product, wheezo®—a smart device designed to revolutionize asthma management. Combining a handheld device with an intuitive e-health app, wheezo® enables users to monitor and manage respiratory conditions effectively.

Key Features of wheezo®

1. Wheeze Detection: Provides an objective measure of airway limitations through breath sound analysis.
2. Data Sharing: Facilitates seamless sharing of health data with caregivers and physicians.
3. Holistic Management: Tracks symptoms, medication use, triggers, and weather conditions to offer a comprehensive asthma management solution.

Impact on Global Health

Respiri (ASX: RSH) aims to reduce hospital admissions and the economic burden of respiratory diseases by empowering users to take control of their health. This mission aligns with global healthcare priorities, making wheezo® a timely and essential tool.

Respiri’s (ASX: RSH) efforts to develop cutting-edge respiratory health solutions, such as the wheezo® device, not only enhance patient outcomes but also address significant economic challenges associated with asthma and chronic respiratory diseases.

Reducing Healthcare Costs

Asthma management is a critical concern worldwide, with billions of dollars spent annually on hospital admissions and emergency care. By providing an easy-to-use tool for monitoring and managing symptoms, Respiri’s (ASX: RSH) wheezo® platform reduces the likelihood of exacerbations that lead to costly hospital visits. This, in turn, alleviates the economic burden on both healthcare systems and individual patients.

Unmanaged asthma can lead to frequent absenteeism and reduced productivity, affecting workplaces globally. wheezo® empowers individuals to stay healthier and more engaged in their daily lives, thereby improving overall workplace performance.

Supporting Preventive Healthcare Trends

Governments and healthcare organizations are increasingly prioritizing preventive care as a cost-effective approach to managing chronic conditions. wheezo® aligns perfectly with this trend, providing proactive tools that emphasize early detection and consistent monitoring.

The Role of Technology in Respiri’s Vision

Respiri’s (ASX: RSH) commitment to leveraging technology is central to its success. The integration of advanced software and hardware in the wheezo® platform underscores the transformative potential of e-health solutions.

Data-Driven Decision Making

The wheezo® device collects and analyzes real-time data on wheeze episodes, giving users actionable insights into their respiratory health. This data can be shared with physicians, enabling tailored treatment plans and adjustments to asthma action plans based on objective metrics.

Artificial Intelligence and Machine Learning

Respiri’s (ASX: RSH) focus on continuous innovation includes exploring AI and machine learning to refine wheeze detection algorithms. These advancements could further enhance the accuracy of wheezo® and provide deeper insights into respiratory patterns.

Seamless Connectivity

The e-health app’s user-friendly interface and cloud-based data sharing capabilities ensure that patients, caregivers, and healthcare providers remain connected, fostering collaborative care. This connectivity also opens doors for integrating wheezo® into broader telemedicine ecosystems.

Global Reach: Addressing Disparities in Respiratory Care

Respiri’s (ASX: RSH) dual operational base in Melbourne, Australia, and New York, USA, reflects its ambition to address respiratory health challenges on a global scale.

Focusing on High-Impact Regions

Countries with high asthma prevalence rates, such as India, China, and parts of Africa, represent significant opportunities for wheezo®. Expanding into these regions could address disparities in access to quality respiratory care.

Adapting to Regional Needs

Respiri’s (ASX: RSH) technology is designed to be adaptable to various healthcare systems, ensuring that it meets the unique demands of different markets. Localized features, such as region-specific weather tracking, make wheezo® particularly effective in diverse environments.

Collaborations with Global Institutions

Partnerships with global health organizations, governments, and NGOs could amplify the impact of Respiri’s (ASX: RSH) innovations, helping to bring affordable, effective asthma management tools to underserved populations.

Strategic Partnerships: Expanding Capabilities

The resolutions passed during the meeting highlight Respiri’s (ASX: RSH) strategic focus on collaborations, such as its partnership with Orb Health, Inc. These alliances are pivotal in:

• Scaling Operations: Joint ventures enable Respiri (ASX: RSH) to expand its market reach and enhance product offerings.
• Leveraging Expertise: Partnering with specialized entities like Orb Health ensures the integration of advanced capabilities into Respiri’s platform.
• Driving Innovation: Collaborative efforts accelerate the development of new features and applications, keeping Respiri at the forefront of respiratory health technology.

Looking Ahead: Respiri’s Growth Trajectory

With strong shareholder support and a clear strategic roadmap, Respiri (ASX: RSH) is poised for significant growth. Key areas of focus include:

1. Market Expansion

Respiri’s (ASX: RSH) dual presence in Australia and the U.S. provides a solid foundation for penetrating new markets, especially in regions with high asthma prevalence.

2. Product Development

Continuous innovation in wheezo®’s functionality ensures its relevance in addressing evolving healthcare needs.

3. Investor Confidence

Transparent governance and successful shareholder meetings enhance investor trust, creating a favorable environment for future fundraising efforts.

Why Shareholder Confidence Matters

The outcomes of Respiri’s (ASX: RSH) general meeting underscore the importance of shareholder confidence in driving corporate success. By aligning with investor expectations, Respiri not only secures the resources needed for growth but also strengthens its market position.

Such alignment is particularly critical in health-tech, where trust and credibility play a pivotal role in adoption and expansion. The results of Respiri Limited’s (ASX: RSH) 2025 General Meeting mark a significant milestone in the company’s journey. With all resolutions passed, Respiri (ASX: RSH) is well-positioned to continue its mission of improving respiratory health worldwide.

As it advances its partnerships, technology, and market presence, Respiri (ASX: RSH) exemplifies the potential of innovation-driven companies to transform healthcare. For investors and stakeholders, the company’s commitment to transparency and strategic growth makes it a compelling entity to watch.